Integrated Organ Support Therapies Market 2033: Advanced Critical Care, Multi-Organ Support & AI-Driven ICU Solutions Power $6.69B Growth

Market Size and Growth

Integrated Organ Support Therapies Market Size reached US$ 4.11 Billion in 2024 and is expected to reach US$ 6.69 Billion by 2033, growing at a CAGR of 5.6% during the forecast period 2025-2033.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/integrated-organ-support-therapies-market?sb

Key Development:

United States: Recent Industry Developments

✅ In September 2025, OrganOx's metra® liver perfusion device received FDA approval for use during air transport. The system preserves donor livers in a normothermic state during flights. This expands access to viable transplant organs across wider geographies.

✅ In August 2025, BMI OrganBank received FDA Breakthrough Device Designation for its kidney preservation and viability-assessment platform. The technology evaluates organ health before transplant. It aims to extend preservation windows and improve transplant outcomes.

✅ In April 2025, Paragonix marked its 100th kidney transplant supported by the FDA-cleared KidneyVault system. The device offers digitally monitored hypothermic perfusion for donor kidneys. It enhances organ protection during transportation.

Japan: Recent Industry Developments

✅ In October 2025, Osaka University and Science Tokyo unveiled UTOpiA, the world's first extracorporeal liver-support system integrating iPS-cell-derived organoids with immune-modulating adsorption columns. The system significantly improved survival in severe liver failure models. It marks a major step toward next-generation organ-support therapy.

✅ In October 2025, researchers confirmed that UTOpiA also promotes measurable liver regeneration in addition to reducing inflammation and injury. The multimodal system functions as both support and regenerative therapy. Plans are underway to prepare for human clinical trials.

✅ In October 2025, Japanese research teams announced development progress aimed at moving UTOpiA toward clinical application within a few years. The work focuses on translating organoid-based biological components into regulated medical products. This signals a strong national push toward regenerative organ-support platforms.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=integrated-organ-support-therapies-market

Recent Mergers and acquisitions

United States: Recent M&A Developments

✅ In October 2025, Terumo completed the acquisition of OrganOx, taking 100% ownership and making it a wholly-owned subsidiary.

✅ In October 2025, the deal valued at approximately US $1.5 billion was officially closed, marking one of the largest medical-tech acquisitions this year.

✅ In August 2025, Terumo signed a definitive agreement (23 August) to acquire all outstanding shares of OrganOx, combining its global device reach with OrganOx's normothermic perfusion platform.

✅ In August 2025, OrganOx which has FDA-cleared NMP (Normothermic Machine Perfusion) technology was positioned for global scale under Terumo's ownership, aiming to improve organ utilization.

Japan: Recent M&A Developments

✅ In October 2025, Japanese medical device leader Terumo completed the acquisition of OrganOx, accelerating its entry into the organ transplantation business.

✅ In August 2025, Terumo announced it would pay US $1.5 billion to acquire OrganOx, reinforcing its strategic push into organ preservation technology.

✅ In August 2025, Terumo formalized a transaction structure to purchase OrganOx on a cash-and-debt-free basis, fully aligning with its long-term organ-support ambitions.

✅ In August 2025, Terumo's acquisition was publicly framed by its leadership as a transformative move into the transplantation space leveraging its device capabilities with OrganOx's NMP innovation.

Key Players:

=> Emulate, Inc., Baxter International, Fresenius Medical Care AG, Getinge AB, LivaNova, Inc., Asahi Kasei Corporation, ADVITOS GmbH, NIHON KOHDEN CORPORATION, Vapotherm, and Fisher & Paykel Healthcare Limited, among others.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/integrated-organ-support-therapies-market?sb

Key Segments:

By Therapy Type
ECMO leads due to high use in critical respiratory and cardiac failure. CRRT follows, driven by rising acute kidney injury cases. ECCO2R sees growing adoption for minimally invasive respiratory support. Liver support systems contribute moderately, while cardiac assist devices remain essential for advanced cardiac failure.

By Modality
Bedside devices dominate ICU usage for continuous life support. Portable/transportable devices grow steadily, enabling emergency and interfacility care. Implantable devices serve specialized long-term cardiac and organ support needs.

By Application
Respiratory failure holds the largest share due to rising ARDS and ECMO use. Cardiac failure contributes strongly, supported by assist devices. Kidney and liver failure segments show stable demand, while multi-organ failure relies on integrated extracorporeal support.

By End-User
Hospitals lead, driven by advanced critical care infrastructure. ICUs follow closely with high ECMO and CRRT usage. Specialty clinics hold a moderate share, while ambulatory surgical centers adopt selective portable systems.

By Region

North America leads the market, supported by advanced critical care infrastructure, high adoption of ECMO and CRRT, and strong clinical expertise.

Europe holds a significant share, driven by established ICU networks and increasing use of multi-organ support therapies.

Asia-Pacific is rapidly expanding, fueled by rising healthcare investment, growing ICU capacity, and increasing incidence of organ failure.

South America shows steady growth, supported by improved critical care access and adoption of renal and cardiac support modalities.

Middle East & Africa represent emerging markets, with development driven by expanding tertiary-care hospitals and rising demand for advanced life-support systems.

FAQ

What is the current size of the Integrated Organ Support Therapies Market?

A: In 2024, the Integrated Organ Support Therapies Market was valued at US$ 4.11 Billion , reflecting its strong industry presence.

Q2: How large is the Integrated Organ Support Therapies Market expected to be by 2033?

A: By 2033, industry forecasts suggest the Integrated Organ Support Therapies Market will grow to around US$ 6.69 Billion, demonstrating significant expansion.

Q3: What is the growth rate of the Integrated Organ Support Therapies Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 5.6% during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.